Landos Recruits New Scientific Director
May 15 2017
BLACKSBURG, VA May 15, 2017 —Landos Biopharma, Inc. (LANDOS) announced today that Dr. Andrew Leber has joined the company to lead efforts aimed at broadening Landos’ therapeutic pipeline and advancing its first-in-class oral therapeutic asset for IBD, known as BT-11 (Lancelot), toward an open investigational new drug (IND) within a year.
Dr. Leber, a graduate of Virginia Tech, joins LANDOS as Scientific Director to build on the Company’s recent successes in the gastrointestinal (GI) space with BT-11, their lead oral first-in-class therapeutic asset for inflammatory bowel disease (IBD).
“I am very excited to participate in the development of an extensive therapeutic pipeline,” says Dr. Leber, LANDOS Scientific Director. He added: “I am familiar with the LANCL2 technology as a therapeutic target for IBD. My first priority will be to complete the remaining IND-enabling studies in order to submit an IND for BT-11, our lead asset for IBD by the first half of 2018.”
“Dr. Leber provides a wealth of experience and knowledge in drug development, modeling, and informatics,” says Dr. Josep Bassaganya-Riera, LANDOS President and CEO. “Dr. Leber’s hard work and dedication, plus his ability to leverage computational methods to accelerate drug development, exemplifies the unwavering commitment of LANDOS to accelerating the path to cures.”
Dr. Leber is a graduate of Penn State University and Virginia Tech. He has degrees in Bioengineering and Genetics, Bioinformatics and Computational Biology. His expertise spans immunology, computational modeling, data analytics, infectious disease, drug development and metabolism with a focus on the integration of these disciplines.
About Landos Biopharma, Inc.
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract
for treatment of inflammatory bowel disease (IBD) and is in Phase 1 clinical testing for Crohn’s disease and ulcerative colitis. Landos also has a robust pipeline of compounds for other autoimmune diseases. For more information, please visit www.landosbiopharma.com or contact email@example.com or follow us @Landosbio.
For Media Requests:
Related Press Releases: